Terms: = Germ cell tumor AND Neurokinin AND Prognosis
14 results:
1. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma.
Ebrahimi S; Mirzavi F; Hashemy SI; Khaleghi Ghadiri M; Stummer W; Gorji A
Biofactors; 2023; 49(4):900-911. PubMed ID: 37092793
[TBL] [Abstract] [Full Text] [Related]
2. The neurokinin-1 Receptor Is Essential for the Viability of Human Glioma cells: A Possible Target for Treating Glioblastoma.
Muñoz MF; Argüelles S; Rosso M; Medina R; Coveñas R; Ayala A; Muñoz M
Biomed Res Int; 2022; 2022():6291504. PubMed ID: 35434136
[TBL] [Abstract] [Full Text] [Related]
3. Plasma neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine tumors of the Small Bowel.
Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP
Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909
[TBL] [Abstract] [Full Text] [Related]
4. In vitro evaluation of
Majkowska-Pilip A; Rius M; Bruchertseifer F; Apostolidis C; Weis M; Bonelli M; Laurenza M; Królicki L; Morgenstern A
Chem Biol Drug Des; 2018 Jul; 92(1):1344-1356. PubMed ID: 29611298
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the neurokinin-1 Receptor System.
Berger M; VON Schweinitz D
Anticancer Res; 2017 Nov; 37(11):5911-5918. PubMed ID: 29061769
[TBL] [Abstract] [Full Text] [Related]
6. β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G
Zhang YX; Li XF; Yuan GQ; Hu H; Song XY; Li JY; Miao XK; Zhou TX; Yang WL; Zhang XW; Mou LY; Wang R
J Biol Chem; 2017 May; 292(21):8933-8947. PubMed ID: 28341744
[TBL] [Abstract] [Full Text] [Related]
7. [Basic and translational research progress of gastrointestinal neuroendocrine neoplasmas].
Song Y; Li X; Song T; Lin G; Chen Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1217-1221. PubMed ID: 27928788
[TBL] [Abstract] [Full Text] [Related]
8. Targeted Radiolabeled Compounds in Glioma Therapy.
Cordier D; Krolicki L; Morgenstern A; Merlo A
Semin Nucl Med; 2016 May; 46(3):243-9. PubMed ID: 27067505
[TBL] [Abstract] [Full Text] [Related]
9. Raised circulating neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering neurokinin A indicates improved prognosis.
Ardill JE; McCance DR; Stronge WV; Johnston BT
Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607
[TBL] [Abstract] [Full Text] [Related]
10. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract] [Full Text] [Related]
11. neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
[TBL] [Abstract] [Full Text] [Related]
12. Validation of neurokinin a assays in the United States and Europe.
Mamikunian P; Ardill JE; O'Dorisio TM; Krutzik SR; Vinik AI; Go VL; Armstrong L; Mamikunian G; Woltering EA
Pancreas; 2011 Oct; 40(7):1000-5. PubMed ID: 21926539
[TBL] [Abstract] [Full Text] [Related]
13. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract] [Full Text] [Related]
14. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.
Ardill JE; Erikkson B
Endocr Relat Cancer; 2003 Dec; 10(4):459-62. PubMed ID: 14713258
[TBL] [Abstract] [Full Text] [Related]
